TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07013747: A Phase 1/2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Participants With Mild Acne

Sponsor: Sanofi Pasteur, a Sanofi Company · Phase: PHASE1/PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 228 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$7,017,600

Rescue Site Savings

+$4,627,230

Unlock Full NCT07013747 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07013747 Rescue Dossier →